Therapeutic drug monitoring in HIV treatment: A literature review

HIV Clinical Trials

Volumn 7, Issue 2, 2006, Pages 59-69

  Wertheimer, Benjamin Z ^a,b   Freedberg, Kenneth A ^b,c   Walensky, Rochelle P ^b   Yazdanapah, Yazdan ^d   Losina, Elena ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d CENTRE HOSPITALIER DE TOURCOING   (France)

Author keywords

Antiretroviral agents; Drug monitoring; HIV

Indexed keywords

AMPRENAVIR; EFAVIRENZ; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG SENSITIVITY; DRUG SPECIFICITY; EVIDENCE BASED MEDICINE; EXPERIMENTAL DESIGN; FEASIBILITY STUDY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INTERMETHOD COMPARISON; INTERVENTION STUDY; MEDLINE; NONHUMAN; OBSERVATIONAL METHOD; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SALVAGE THERAPY; STEADY STATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRAL GENETICS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG MONITORING; FEASIBILITY STUDIES; HIV INFECTIONS; HUMANS; REVIEW LITERATURE; VIRAL LOAD;

EID: 33746109519     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/32CG-U6V0-NPTC-EQBK     Document Type: Article

References (41)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
3. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
4. Casado JL, Perez-Elias MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS. 1998;12:F131-135.
5. Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS. 1999;13:F71-77.
6. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
7. Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS. 2002;16:2311-2315.
8. Mallolas J, Blanco JL, Sarasa M, et al. Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients. J Acquir Immune Defic Syndr. 2000,25:229-235.
9. Casado JL, Moreno A, Sabido R, et al. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. HIV Clin Trials. 2000;1:13-19.
10. Seminari E, Maggiolo F, Villani P, et al. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors. J Acquir Immune Defic Syndr. 1999;22:453-460.
11. Barry MG, Merry C, Lloyd J, et al. Variability in trough plasma saquinavir concentrations in HIV patients - a case for therapeutic drug monitoring. Br J Clin Pharmacol. 1998;45:501-502.
12. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002,16 (suppl 1):S5-37.
13. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS. 1996;10:485-492.
14. Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther. 1998,3:215-220.
15. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995;171:537-545.
16. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 2001;15:1089-1095.
17. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930-937.
18. Hoetelmans RM, Reijers MH, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS. 1998;12:F111-115.
19. Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis. 1999;179:1116-1123.
20. Aries SP, Schaaf BM, Wilmsen U, et al. Routine therapeutic drug monitoring in patients on protease inhibitors: impact on therapeutic decisions? 5th International Congress on Drug Therapy in HIV Infection [abstract P264 A]. AIDS. 2000, 14(suppl 4):S91.
21. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS. 1999;13:473-478.
22. Lloyd J, Maher B, Khoo S, Gibbons S, Back D. The feasibility of therapeutic drug monitoring for protease inhibitors [abstract]. In: Program and abstracts from the 6th Annual Conference of the British HIV Association; March 2000; Edinburgh, Scotland.
23. Martinavarro-Dominguez A, Capella-Peiro ME, Gil-Agusti M, Marcos-Tomas JV, Esteve-Romero J. Therapeutic drug monitoring of anticonvulsant drugs by micellar HPLC with direct injection of serum samples. Clin Chem. 2002;48:1696-1702.
24. Abendroth D. Experience with therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36:426S-429S.
25. Begg EJ, Barclay ML. Aminoglycosides - 50 years on. Br J Clin Pharmacol. 1995;39:597-603.
26. Recommendations du Groupe d'Experts. Rapport 2000 Sous la Direction du Pr JF Delfraissy. Prise en Charge Therapeutique des Personnes Infectees par le VIH. Paris: Medecine-Sciences, Flamarion; 2000.
27. Doerr HW, Brockmeyer NH, Salzberger B, Marcus U, Brodt HR. Antiretrovirale Therapie der HIV-Infektion. Deutsches Arzteblatt. 2001;4:175-181.
28. Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS. 2001,15:991-998.
29. Burger DM, Hugen PW, Aarnoutse RE, et al. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr. 2001;26:218-224.
30. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003;17:1157-1165.
31. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002;16:551-560.
32. Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 2004;5:352-359.
33. Duval X, Mentre F, Lamotte C, et al. Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort. Ther Drug Monit. 2005;27:63-70.
34. Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis. 1998;177:1533-1540.
35. Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS. 2002;16:1331-1340.
36. Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ ritonavir (KALEPHAR study). AIDS. 2004;18:1305-1310.
37. Stahle L, Moberg L, Svensson JO, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit. 2004;26:267-270.
38. Burger DM, Hugen PW, Aarnoutse RE, et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit. 2003;25:73-80.
39. Rayner CR, Galbraith KJ, Marriott JL, Duncan GJ. A critical evaluation of the therapeutic range of indinavir. Ann Pharmacother. 2002;36:1230-1237.
40. John L, Marra F, Ensom MH. Role of therapeutic drug monitoring for protease inhibitors. Ann Pharmacother. 2001;35:745-754.
41. Molto J, Clotet B. Therapeutic drug monitoring of antiretroviral agents scenario. J HIV Ther. 2004;9:75-78.